Lorlatinib Is Well Tolerated and Has Activity in ALK+ and ROS1+ NSCLC [Research Watch]

Lorlatinib achieved systemic and intracranial responses in patients with ALK- and ROS1-positive NSCLC.

from Cancer via ola Kala on Inoreader http://ift.tt/2zvyBAg
via IFTTT